CLINICAL TRIALS PROFILE FOR TECHNETIUM TC-99M SESTAMIBI

All Clinical Trials for Technetium Tc-99m Sestamibi

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00162045 ↗	A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects	Completed	Lantheus Medical Imaging	Phase 1/Phase 2	2005-01-01	The purpose of this Phase I-II multicenter clinical trial is to establish dosimetry and safety profiles for CARDIOLITE® (Technetium Tc99m Sestamibi) in pediatric subjects.
NCT00162071 ↗	A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging	Terminated	Forest Laboratories	Phase 2	2005-07-01	The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.
NCT00560495 ↗	Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer	Withdrawn	National Cancer Institute (NCI)	Phase 1	2007-05-01	RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving radiation therapy together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
NCT00560495 ↗	Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer	Withdrawn	Roswell Park Cancer Institute	Phase 1	2007-05-01	RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving radiation therapy together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
NCT00767468 ↗	Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis	Terminated	National Cancer Institute (NCI)	Phase 1	2008-10-01	RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in treating patients with locally advanced or metastatic liver cancer and cirrhosis.
NCT00767468 ↗	Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis	Terminated	UNC Lineberger Comprehensive Cancer Center	Phase 1	2008-10-01	RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in treating patients with locally advanced or metastatic liver cancer and cirrhosis.
NCT00912301 ↗	Cheno Effect on Transit in Health and IBS-C	Completed	National Center for Research Resources (NCRR)	Phase 2	2009-04-01	The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid, induces acceleration of colonic transit in health and in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).

Clinical Trial Conditions for Technetium Tc-99m Sestamibi

Condition Name

Condition Name for Technetium Tc-99m Sestamibi
Intervention	Trials
Estrogen Receptor Negative	1
HER2/Neu Negative	1
Ischemic Heart Disease	1
Kawasaki Disease	1

Condition MeSH

Condition MeSH for Technetium Tc-99m Sestamibi
Intervention	Trials
Syndrome	2
Cardiovascular Diseases	1
Carcinoma, Hepatocellular	1
Breast Neoplasms	1

Clinical Trial Locations for Technetium Tc-99m Sestamibi

Trials by Country

Trials by Country for Technetium Tc-99m Sestamibi
Location	Trials
United States	13
Taiwan	1
Canada	1

Trials by US State

Trials by US State for Technetium Tc-99m Sestamibi
Location	Trials
Minnesota	2
New York	2
Washington	1
South Carolina	1
Pennsylvania	1

Clinical Trial Progress for Technetium Tc-99m Sestamibi

Clinical Trial Phase

Clinical Trial Phase for Technetium Tc-99m Sestamibi
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	2
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for Technetium Tc-99m Sestamibi
Clinical Trial Phase	Trials
Completed	3
Terminated	2
Recruiting	1

Clinical Trial Sponsors for Technetium Tc-99m Sestamibi

Sponsor Name

Sponsor Name for Technetium Tc-99m Sestamibi
Sponsor	Trials
National Cancer Institute (NCI)	3
Mayo Clinic	2
M.D. Anderson Cancer Center	1

Sponsor Type

Sponsor Type for Technetium Tc-99m Sestamibi
Sponsor	Trials
NIH	5
Other	5
Industry	3

Clinical Trials Update, Market Analysis, and Projection for Technetium Tc-99m Sestamibi

Last updated: November 1, 2025

Introduction

Technetium Tc-99m Sestamibi (MIBI) remains a cornerstone radiopharmaceutical in nuclear medicine, primarily used for myocardial perfusion imaging, parathyroid, and breast tumor detection. With its established clinical utility and expanding applications, understanding recent clinical trial developments, market dynamics, and future projections is essential for stakeholders, including pharmaceutical companies, healthcare providers, and investors.

---

Clinical Trials Update

Recent Developmental Trends

In the last five years, clinical research on Technetium Tc-99m Sestamibi has largely focused on expanding its diagnostic scope, optimizing imaging protocols, and assessing safety profiles. According to ClinicalTrials.gov, over 80 active or completed trials involve Tc-99m Sestamibi, primarily in oncology, cardiac diagnostics, and surgical applications.

Emerging Indications and Protocols

• Oncology Applications: Emerging studies explore Tc-99m Sestamibi for detecting auxillary tumor recurrence, evaluating multiple myeloma, and assessing metastatic spread, especially in lymphoma and breast cancer. Novel protocols optimize dosing and imaging timing to improve sensitivity and specificity.

• Cardiac Imaging Enhancements: Recent trials test high-resolution SPECT imaging techniques to reduce false positives and improve quantitation, with some exploring hybrid imaging modalities combining Tc-99m Sestamibi with CT or MRI.

• Breast Cancer Detection: Several studies investigate Tc-99m Sestamibi’s potential for contrast-enhanced multi-parametric imaging, providing better tumor characterization and aiding in surgical planning.

Safety and Efficacy Data

Clinical trials consistently affirm the safety profile of Tc-99m Sestamibi, with adverse reactions being rare and generally mild. Efficacy improvements stem from advances in detector technology and software, rather than changes to the radiotracer itself. Such developments validate continued reliance on Tc-99m Sestamibi, with current research underscoring its versatility across diagnostic domains.

---

Market Analysis

Market Size and Growth Drivers

The global nuclear medicine market, valued at approximately USD 7.5 billion in 2022, encompasses radiopharmaceuticals like Tc-99m Sestamibi, which dominates cardiology and oncology diagnostics. The compound holds about 30-40% market share within the radiopharmaceuticals segment, driven by its widespread clinical adoption.

Key growth drivers include:

• Rising prevalence of cardiovascular diseases and cancers.
• Increasing demand for minimally invasive diagnostic procedures.
• Technological advancements increasing imaging resolution.
• Expanding applications in surgical and intraoperative contexts.

Manufacturing and Supply Chain Dynamics

The short half-life of Technetium-99m (6 hours) complicates manufacturing, requiring a robust, decentralized supply chain. The global reliance on aging molybdenum-99 (Mo-99) generators impacts market stability, prompting investments in reactor replacements and alternative production methods.

Competitive Landscape

Main competitors include other technetium-based agents such as Tc-99m Sestamibi’s alternative radiopharmaceuticals like Tc-99m Tetrofosmin and newer PET tracers. Although direct competition is limited given Tc-99m Sestamibi’s established role, emerging PET compounds may challenge its dominance in specific indications.

Regulatory Environment

Regulatory agencies, notably the FDA and EMA, maintain rigorous standards for radiopharmaceutical approval. Recent approvals include updated labeling reflecting expanded indications and improved imaging protocols. Regulatory flexibility, especially concerning supply chain constraints, influences market stability.

---

Market Projection and Future Outlook

Short-term (Next 3 Years)

The immediate outlook remains positive, with steady growth driven by ongoing clinical validation, increased utilization in developed markets, and technological improvements. The adoption of hybrid imaging techniques combining Tc-99m Sestamibi enhances diagnostic accuracy, fostering increased demand.

Long-term (Next 5-10 Years)

Projected compound annual growth rate (CAGR) of approximately 4-6% hinges on several factors:

• Innovation: The development of hybrid SPECT-CT and SPECT-MRI platforms boosts the utility of existing radiotracers.
• Emerging Technologies: PET tracers labeled with isotopes like Fluorine-18 could potentially replace SPECT agents for certain indications, yet Tc-99m Sestamibi retains a cost advantage.
• Supply Chain Improvements: Broader Mo-99 availability and alternative production methods will stabilize supply, enabling sustained market growth.

Potential Disruptors

• Emerging PET Radiotracers: Agents like F-18 FDG and PSMA tracers could challenge Tc-99m Sestamibi's dominance in some oncology applications.
• Regulatory and Environmental Factors: Stricter regulations on radiopharmaceutical production and waste management might impact manufacturing costs.

---

Key Takeaways

• Established Clinical Utility: Tc-99m Sestamibi remains a mainstay in cardiac, oncologic, and surgical imaging, with ongoing clinical trials validating its expanding indications.
• Market Stability and Growth: The global market is expected to grow at 4-6% CAGR over the next decade, driven by technological advancements, persistent demand, and supply chain improvements.
• Supply Chain Challenges: The short half-life of Tc-99m necessitates a resilient production and distribution network, with innovations in Mo-99 supply crucial for long-term stability.
• Emerging Technologies: PET tracers and hybrid imaging modalities offer competitive pressure but are unlikely to displace Tc-99m Sestamibi in cost-sensitive, resource-constrained settings.
• Regulatory and Environmental Considerations: Navigating evolving regulatory standards and waste management policies will influence market dynamics and production costs.

---

FAQs

1. What are the primary clinical indications for Technetium Tc-99m Sestamibi?
Tc-99m Sestamibi is predominantly used for myocardial perfusion imaging, localization of parathyroid adenomas, and breast tumor detection, owing to its ability to localize in mitochondria-rich tissues.

2. How is recent research shaping the future use of Tc-99m Sestamibi?
Recent trials focus on enhancing imaging protocols, integrating hybrid modalities, and exploring new indications such as lymphoma assessment and intraoperative tumor localization, which could broaden its clinical applications.

3. What are the main supply challenges facing Tc-99m Sestamibi?
The isotope’s short half-life demands a stable Mo-99 supply, which is dependent on aging reactors and complex production logistics. Supply disruptions can impact availability and market stability.

4. How does technological innovation impact the market projection of Tc-99m Sestamibi?
Advances in imaging hardware improve diagnostic accuracy and efficiency, supporting continued demand. However, competition from PET tracers could influence market share and future growth.

5. What regulatory factors could influence the market outlook for Tc-99m Sestamibi?
Regulatory efforts aimed at environmental safety, waste management, and supply chain security, alongside approvals of new indications, will shape the regulatory landscape and market trajectory.

---

References

[1] ClinicalTrials.gov. (2023). Trials involving Tc-99m Sestamibi.
[2] MarketsandMarkets. (2022). Nuclear Medicine Market Report.
[3] WHO. (2019). Molybdenum-99 supply: Challenges and solutions.
[4] Society of Nuclear Medicine and Molecular Imaging (SNMMI). (2022). Advances in SPECT imaging protocols.